WASHINGTON, D.C. -- July 15, 2013 -- Dr. Jeffrey Trent, President and Research Director for the Translational Genomics Research Institute (TGen), will discuss state-of-the-art genomics research July 16 at the Brookings Institution.
Dr. Trent, Ph.D., F.A.C.M.G., and former Scientific Director of the National Human Genome Research Institute, is part of a panel, Innovation in Action, at Brookings' 2nd annual State of Biomedical Innovation Conference, which will focus on the use of novel data sources to improve medical product development and care delivery.
Specifically, Dr. Trent will discuss TGen's ongoing work in translating genomics research into clinical benefit. TGen is one of a very few centers who are using the entire human genome in clinical trials in order to diagnose or make treatment decisions for an individual patient (precision medicine).
"The human genome will be the medical textbook for the next century and beyond," Dr. Trent said. "By harnessing the power of the human genome, we will provide immeasurable patient benefit while at the same time reducing the time and costs of diagnosis and treatment. TGen is a global leader in clinical trials that deploy this form of innovative research."
TGen's translational model enables pioneering discoveries in the laboratory to be quickly moved to clinical trials where they can be used to immediately benefit patients with many types of cancer and other debilitating diseases.
Dr. Trent's panel will be moderated by Dr. Mark B. McClellan, Director and Fellow of Brookings' Initiative on Innovation and Value in Health Care. He is the former administrator for the Centers for Medicare and Medicaid Services (2004-2006), and the former commissioner of the Food and Drug Administration (2002-2004). He also served as a member of the President's Council of Economic Advisers, and as senior director for health care policy at the White House (2001-2002). In these positions, he developed and implemented major reforms in health policy.
This conference is being convened by the Engelberg Center for Health Care Reform at Brookings, which was established to help turn ideas for health care reform into action, including reducing gaps in insurance coverage and ensuring health care affordability. Its mission is to develop data-driven, practical policy solutions that promote broad access to high-quality, affordable and innovative care in the United States. The Center also conducts research, makes policy recommendations, and facilitates development of new consensus around key issues, providing technical support to implement and evaluate new solutions in collaboration with a broad range of stakeholders.
The conference is scheduled for 9 a.m.-12:30 p.m. EDT July 16 at the Brookings Institution, Falk Auditorium, 1775 Massachusetts Avenue, N.W., Washington, D.C. Dr. Trent's hour-long panel is scheduled to start at 10:10 a.m. The event will be streamed live on the Brookings website: http://www.brookings.edu/events/2013/07/16-biomedical-innovation.
About the Brookings Institution
The Brookings Institution is a nonprofit public policy organization based in Washington, DC. Our mission is to conduct high-quality, independent research and, based on that research, to provide innovative, practical recommendations that advance three broad goals: strengthen American democracy; foster the economic and social welfare, security and opportunity of all Americans; and secure a more open, safe, prosperous and cooperative international system. Brookings is proud to be consistently ranked as the most influential, most quoted and most trusted think tank. More information: http://www.brookings.edu.
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: http://www.tgen.org.
TGen Senior Science Writer
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.